{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:47:40Z","timestamp":1792784860197,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00647"],"award-info":[{"award-number":["PI22\/00647"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI25\/00571"],"award-info":[{"award-number":["PI25\/00571"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00647"],"award-info":[{"award-number":["PI22\/00647"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI25\/00571"],"award-info":[{"award-number":["PI25\/00571"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CRIS Cancer Foundation, grant number: TRANSPHYSTALENT_23_6","id":[{"id":"https:\/\/ror.org\/009yhf078","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41409-026-02984-0","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:53:57Z","timestamp":1784962437000},"page":"1396-1404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Autologous stem cell transplantation in POEMS syndrome: Multicenter real-world treatment patterns and outcomes"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5694-0921","authenticated-orcid":false,"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7568-2527","authenticated-orcid":false,"given":"Anna","family":"de Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Carro Arostegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago","family":"Arribas Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-8909","authenticated-orcid":false,"given":"Mercedes","family":"Gironella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Verge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Escoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0706-9046","authenticated-orcid":false,"given":"Carles","family":"Tolosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Mar\u00eda","family":"Mart\u00ed-Tutusaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Baca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e8nia","family":"Abella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Motll\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"L\u00f3pez-Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-2221","authenticated-orcid":false,"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Castillo-Gir\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Teresa","family":"Cibeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-9255","authenticated-orcid":false,"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"2984_CR1","first-page":"311","volume":"59","author":"PA Bardwick","year":"1980","unstructured":"Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Rep Two Cases Rev Lit Med. 1980;59:311\u201322.","journal-title":"Rep Two Cases Rev Lit Med"},{"key":"2984_CR2","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","volume":"101","author":"A Dispenzieri","year":"2003","unstructured":"Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101:2496\u2013506.","journal-title":"Blood"},{"key":"2984_CR3","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1002\/ajh.27081","volume":"98","author":"A Dispenzieri","year":"2023","unstructured":"Dispenzieri A. POEMS syndrome: Update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1934\u201350.","journal-title":"Am J Hematol"},{"key":"2984_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/hematology.2025000729","volume":"2025","author":"A Dispenzieri","year":"2025","unstructured":"Dispenzieri A. POEMS syndrome: diagnosis, treatments, and outcomes. Hematol Am Soc Hematol Educ Program. 2025;2025:393\u2013400.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2984_CR5","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jamaoncol.2021.0586","volume":"7","author":"J Khouri","year":"2021","unstructured":"Khouri J, Nakashima M, Wong S. Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome: A Review. JAMA Oncol. 2021;7:1383\u201391.","journal-title":"JAMA Oncol"},{"key":"2984_CR6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/art.1780400430","volume":"40","author":"M Soubrier","year":"1997","unstructured":"Soubrier M, Dubost JJ, Serre AF, Ristori JM, Sauvezie B, Cathebras P, et al. Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum. 1997;40:786\u20137.","journal-title":"Arthritis Rheum"},{"key":"2984_CR7","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood.V87.4.1458.bloodjournal8741458","volume":"87","author":"RK Gherardi","year":"1996","unstructured":"Gherardi RK, B\u00e9lec L, Soubrier M, Malapert D, Zuber M, Viard JP, et al. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood. 1996;87:1458\u201365.","journal-title":"Blood"},{"key":"2984_CR8","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/(SICI)1097-4598(199811)21:11<1390::AID-MUS5>3.0.CO;2-4","volume":"21","author":"O Watanabe","year":"1998","unstructured":"Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, et al. Overproduction of vascular endothelial growth factor\/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve. 1998;21:1390\u20137.","journal-title":"Muscle Nerve"},{"key":"2984_CR9","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1182\/blood-2011-06-362392","volume":"118","author":"A D\u2019Souza","year":"2011","unstructured":"D\u2019Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood. 2011;118:4663\u20135.","journal-title":"Blood"},{"key":"2984_CR10","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/s41375-025-02659-7","volume":"39","author":"J Cook","year":"2025","unstructured":"Cook J, Warsame R, Omar M, Buadi FK, Abdallah N, Dingli D, et al. Interleukin-6 is a highly prognostic biomarker for POEMS syndrome. Leukemia. 2025;39:2281\u20134.","journal-title":"Leukemia"},{"key":"2984_CR11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3324\/haematol.2023.283719","volume":"109","author":"F Autore","year":"2024","unstructured":"Autore F, Bramanti S, Lessi F, Innocenti I, Galli E, Rocchi S, et al. What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome? Haematologica. 2024;109:888\u201394.","journal-title":"Haematologica"},{"key":"2984_CR12","doi-asserted-by":"publisher","first-page":"E72","DOI":"10.1002\/ajh.25375","volume":"94","author":"NY Saini","year":"2019","unstructured":"Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, et al. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol. 2019;94:E72\u20134.","journal-title":"Am J Hematol"},{"key":"2984_CR13","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1182\/bloodadvances.2022007218","volume":"6","author":"A Kansagra","year":"2022","unstructured":"Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, et al. Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Adv. 2022;6:3991\u20135.","journal-title":"Blood Adv"},{"key":"2984_CR14","first-page":"207.e1","volume":"30","author":"AA Li","year":"2024","unstructured":"Li AA, Gao XM, Zhao H, Shen KN, Zhang L, Cao XX, et al. Long-Term Outcomes of Autologous Stem Cell Transplantation in Patients with Newly Diagnosed POEMS Syndrome. Transpl Cell Ther. 2024;30:207.e1\u2013207.e7.","journal-title":"Transpl Cell Ther"},{"key":"2984_CR15","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1038\/s41409-021-01395-7","volume":"56","author":"AK Baa","year":"2021","unstructured":"Baa AK, Chellapuram SK, Sharma A, Malik PS, Sahoo RK, Biswas A, et al. Poems syndrome: consolidation with autologous stem cell transplantation. Bone Marrow Transpl. 2021;56:2597\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2984_CR16","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1111\/bjh.16057","volume":"186","author":"O Tomkins","year":"2019","unstructured":"Tomkins O, Keddie S, Lunn MP, D\u2019Sa S. High-dose therapy and autologous transplantation for POEMS Syndrome: effective, but how to optimise? Br J Haematol. 2019;186:e178\u201381.","journal-title":"Br J Haematol"},{"key":"2984_CR17","doi-asserted-by":"publisher","first-page":"e796","DOI":"10.1097\/HS9.0000000000000796","volume":"6","author":"S D\u2019Sa","year":"2022","unstructured":"D\u2019Sa S, Khwaja J, Keddie S, Keh RY, Smyth D, Ronneberger R, et al. Comprehensive Diagnosis and Management of POEMS Syndrome. HemaSphere. 2022;6:e796.","journal-title":"HemaSphere"},{"key":"2984_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/sj.bmt.1703015","volume":"27","author":"TR Spitzer","year":"2001","unstructured":"Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transpl. 2001;27:893\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2984_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/sj.bmt.1703855","volume":"31","author":"A Maiolino","year":"2003","unstructured":"Maiolino A, Biasoli I, Lima J, Portugal AC, Pulcheri W, Nucci M. Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria. Bone Marrow Transpl. 2003;31:393\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2984_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/bjh.18400","volume":"200","author":"J Khwaja","year":"2023","unstructured":"Khwaja J, D\u2019Sa S, Lunn MP, Sive J. Evidence-based medical treatment of POEMS syndrome. Br J Haematol. 2023;200:128\u201336.","journal-title":"Br J Haematol"},{"key":"2984_CR21","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/leu.2017.27","volume":"31","author":"J Li","year":"2017","unstructured":"Li J, Duan MH, Wang C, Huang XF, Zhang W, Cao XX, et al. Impact of pretransplant induction therapy on autologous stem cell transplantation for patients with newly diagnosed POEMS syndrome. Leukemia. 2017;31:1375\u201381.","journal-title":"Leukemia"},{"key":"2984_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3324\/haematol.2016.148460","volume":"102","author":"G Cook","year":"2017","unstructured":"Cook G, Iacobelli S, van Biezen A, Ziagkos D, LeBlond V, Abraham J, et al. High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. Haematologica. 2017;102:160\u20137.","journal-title":"Haematologica"},{"key":"2984_CR23","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood-2017-07-795385","volume":"131","author":"C Ohwada","year":"2018","unstructured":"Ohwada C, Sakaida E, Kawajiri-Manako C, Nagao Y, Oshima-Hasegawa N, Togasaki E, et al. Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood. 2018;131:2173\u20136.","journal-title":"Blood"},{"key":"2984_CR24","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.bbmt.2018.01.026","volume":"24","author":"C Kawajiri-Manako","year":"2018","unstructured":"Kawajiri-Manako C, Sakaida E, Ohwada C, Miyamoto T, Azuma T, Taguchi J, et al. Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in Japan. Biol Blood Marrow Transpl. 2018;24:1180\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2984_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1182\/blood-2012-04-423178","volume":"120","author":"A D\u2019Souza","year":"2012","unstructured":"D\u2019Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood. 2012;120:56\u201362.","journal-title":"Blood"},{"key":"2984_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clml.2021.10.007","volume":"22","author":"A Jurczyszyn","year":"2022","unstructured":"Jurczyszyn A, Castillo JJ, Olszewska-Szopa M, Kumar L, Thibaud S, Richter J, et al. POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. Clin Lymphoma Myeloma Leuk. 2022;22:297\u2013304.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2984_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3324\/haematol.2010.030882","volume":"96","author":"C Fern\u00e1ndez de Larrea","year":"2011","unstructured":"Fern\u00e1ndez de Larrea C, Tovar N, Cibeira MT, Ar\u00f3stegui JI, Rosi\u00f1ol L, Elena M, et al. Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents. Haematologica. 2011;96:171\u20133.","journal-title":"Haematologica"},{"key":"2984_CR28","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3324\/haematol.2013.084350","volume":"98","author":"N Tovar","year":"2013","unstructured":"Tovar N, de Larrea CF, Ar\u00f3stegui JI, Cibeira MT, Rosi\u00f1ol L, Rovira M, et al. Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution. Haematologica. 2013;98:1142\u20136.","journal-title":"Haematologica"},{"key":"2984_CR29","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.bbmt.2017.04.012","volume":"23","author":"LG Rodr\u00edguez-Lobato","year":"2017","unstructured":"Rodr\u00edguez-Lobato LG, Fern\u00e1ndez de Larrea C, Cibeira MT, Tovar N, Ar\u00f3stegui JI, Rosi\u00f1ol L, et al. Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis. Biol Blood Marrow Transpl. 2017;23:1269\u201375.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2984_CR30","doi-asserted-by":"publisher","first-page":"e009157","DOI":"10.1136\/bmjopen-2015-009157","volume":"5","author":"S Misawa","year":"2015","unstructured":"Misawa S, Sato Y, Katayama K, Hanaoka H, Sawai S, Beppu M, et al. Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study. BMJ Open. 2015;5:e009157.","journal-title":"BMJ Open"},{"key":"2984_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0073-8","volume":"8","author":"H Zhao","year":"2018","unstructured":"Zhao H, Cai H, Wang C, Huang Xfei, Cao Xxin, Zhang L, et al. Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome. Blood Cancer J. 2018;8:37.","journal-title":"Blood Cancer J"},{"key":"2984_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70049","volume":"43","author":"F Autore","year":"2025","unstructured":"Autore F, Mannina D, Lessi F, Galli E, Oliva S, Derudas D, et al. VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation. Hematol Oncol. 2025;43:e70049.","journal-title":"Hematol Oncol"},{"key":"2984_CR33","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/leu.2015.344","volume":"30","author":"TV Kourelis","year":"2016","unstructured":"Kourelis TV, Buadi FK, Gertz MA, Lacy MQ, Kumar SK, Kapoor P, et al. Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia. 2016;30:1079\u201385.","journal-title":"Leukemia"},{"key":"2984_CR34","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41409-023-02047-8","volume":"58","author":"AA Li","year":"2023","unstructured":"Li AA, Yu YY, Gao XM, Zhao H, Cao XX, Zhang L, et al. Treatment and outcome of second-line therapy for POEMS syndrome after autologous stem cell transplantation. Bone Marrow Transpl. 2023;58:1167\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2984_CR35","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1182\/bloodadvances.2020001492","volume":"4","author":"Z Sayar","year":"2020","unstructured":"Sayar Z, Weatherill A, Keddie S, Sive J, Lunn MP, Thomas M, et al. High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry. Blood Adv. 2020;4:2139\u201342.","journal-title":"Blood Adv"},{"key":"2984_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ajh.26422","volume":"97","author":"PW Mellors","year":"2022","unstructured":"Mellors PW, Kourelis T, Go RS, Muchtar E, Gertz MA, Kumar SK, et al. Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. Am J Hematol. 2022;97:209\u201315.","journal-title":"Am J Hematol"},{"key":"2984_CR37","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41375-024-02489-z","volume":"39","author":"K Lee","year":"2025","unstructured":"Lee K, Kourelis T, Tschautscher M, Warsame R, Buadi F, Gertz M, et al. Capillary leak phenotype as a major cause of death in patients with POEMS syndrome. Leukemia. 2025;39:703\u20139.","journal-title":"Leukemia"},{"key":"2984_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1600-0609.2008.01037.x","volume":"80","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri A, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, et al. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol. 2008;80:397\u2013406.","journal-title":"Eur J Haematol"},{"key":"2984_CR39","doi-asserted-by":"publisher","first-page":"e0241778","DOI":"10.1371\/journal.pone.0241778","volume":"15","author":"LG Rodr\u00edguez-Lobato","year":"2020","unstructured":"Rodr\u00edguez-Lobato LG, Mart\u00ednez-Roca A, Casta\u00f1o-D\u00edez S, Palomino-Mosquera A, Guti\u00e9rrez-Garc\u00eda G, Pedraza A, et al. The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. PLoS ONE. 2020;15:e0241778.","journal-title":"PLoS ONE"},{"key":"2984_CR40","doi-asserted-by":"publisher","first-page":"e775","DOI":"10.1016\/j.clml.2021.06.004","volume":"21","author":"B Dhakal","year":"2021","unstructured":"Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D\u2019Souza A, et al. Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021;21:e775\u201381.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2984_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/hon.2813","volume":"39","author":"C Betticher","year":"2021","unstructured":"Betticher C, Bacher U, Legros M, Zimmerli S, Banz Y, Mansouri Taleghani B, et al. Prophylactic corticosteroid use prevents engraftment syndrome in patients after autologous stem cell transplantation. Hematol Oncol. 2021;39:97\u2013104.","journal-title":"Hematol Oncol"},{"key":"2984_CR42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","volume":"15","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15:333\u201342.","journal-title":"Lancet Oncol"},{"key":"2984_CR43","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41375-021-01293-3","volume":"35","author":"F Maura","year":"2021","unstructured":"Maura F, Weinhold N, Diamond B, Kazandjian D, Rasche L, Morgan G, et al. The mutagenic impact of melphalan in multiple myeloma. Leukemia. 2021;35:2145\u201350.","journal-title":"Leukemia"},{"key":"2984_CR44","doi-asserted-by":"publisher","first-page":"E291","DOI":"10.1002\/ajh.27050","volume":"98","author":"D Dima","year":"2023","unstructured":"Dima D, Valent J, Khouri J. Daratumumab monotherapy for relapsed POEMS syndrome. Am J Hematol. 2023;98:E291\u20134.","journal-title":"Am J Hematol"},{"key":"2984_CR45","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-018-0672-7","volume":"11","author":"J Xu","year":"2018","unstructured":"Xu J, Wang Q, Xu H, Gu C, Jiang L, Wang J, et al. Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. J Hematol OncolJ Hematol Oncol. 2018;11:128.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"2984_CR46","first-page":"2859","volume":"110","author":"M Williams","year":"2025","unstructured":"Williams M, Atanackovic D, Mulatu R, Matsangos A, Yamoah D, Badros A. Cilta-cel CAR T cells as an effective and well tolerated treatment for POEMS: a case study. Haematologica. 2025;110:2859\u201363.","journal-title":"Haematologica"},{"key":"2984_CR47","doi-asserted-by":"publisher","unstructured":"Talbot A, Forgeard N, Vaugeois T, Theves F, Dimassi S, Royer B, et al. Teclistamab for heavily pretreated relapsed \/ refractory POEMS syndrome. Haematologica. 2025. https:\/\/doi.org\/10.3324\/haematol.2025.287606.","DOI":"10.3324\/haematol.2025.287606"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02984-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02984-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02984-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:59:44Z","timestamp":1791554384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02984-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2984"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02984-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Luis Gerardo Rodr\u00edguez-Lobato: Honoraria and travel grants from Janssen, Amgen, GSK, BMS, Sanofi, and Menarini Stemline; Anna de Daniel: Honoraria from Janssen, travel grants from Sanofi, Janssen, Binding Side; M. Teresa Cibeira: Honoraria from Janssen, Sanofi, GSA, Amgen, and Pfizer; Laura Rosi\u00f1ol: Honoraria from BMS, Celgene, Amgen, Takeda, Sanofi, Janssen, GSK; Josep Mar\u00eda Mart\u00ed Tutusaus: Honoraria from Janssen, Pfizer and Menarini Stemline; Anna Sureda: Honoraria: Takeda, BMS\/Celgene, MSD, Novartis, Gilead Kite, Sanofi, Roche, GenMab, Abbvie, Jazz Pharmaceuticals; Consultancy: Takeda, BMS\/Celgene, Novartis, Janssen, Gilead, Sanofi, GenMab, Abbvie; Speaker\u2019s Bureau: Takeda; Research Support: Takeda; Carlos Fern\u00e1ndez de Larrea: Consultancy: BeiGene, Sanofi, GSK, BMS, Janssen; Honoraria: BeiGene, Pfizer, Sanofi, GSK, Takeda, BMS, Janssen; Research Funding: Takeda, Amgen, BMS, Janssen. The rest of the authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}